ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
Want to see JP:4886 full AI Analyst Report?
Top Page
ASKA Pharmaceutical Holdings Co., Ltd.
(4886)
Select Model
Select Model
Rating:78Outperform
Price Target:
¥3,308.00
▲(62.32% Upside)
Action:Reiterated
Date:05/12/26
The score is driven primarily by strong financial positioning (notably major debt reduction and expanding equity) and steady revenue growth, tempered by historically volatile cash flow. Technicals add support via a clear uptrend and positive momentum, while valuation is favorable due to a low P/E and a moderate dividend yield.
Positive Factors
Strengthened balance sheet / low leverage
Material deleveraging and expanding equity materially reduce financial risk and increase strategic optionality. A low debt base supports funding R&D, shields the company from reimbursement shocks, and enables capex or M&A without stressing liquidity over the medium term.
Negative Factors
Volatile operating and free cash flow
Irregular cash conversion reduces predictability for funding R&D, dividends, or strategic investments. Variability suggests sensitivity to working capital, timing of receipts/payments or investment cycles, increasing execution risk despite recent recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened balance sheet / low leverage
Material deleveraging and expanding equity materially reduce financial risk and increase strategic optionality. A low debt base supports funding R&D, shields the company from reimbursement shocks, and enables capex or M&A without stressing liquidity over the medium term.
Read all positive factors
ASKA Pharmaceutical Holdings Co., Ltd. (4886) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥79.70B
Dividend Yield2.52%
Average Volume (3M)49.10K
Price to Earnings (P/E)12.3
Beta (1Y)0.54
Revenue Growth10.90%
EPS Growth6.20%
CountryJP
Employees762
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)178.85
Shares Outstanding28,763,199
10 Day Avg. Volume37,820
30 Day Avg. Volume49,100
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)0.96
Price to Sales (P/S)0.94
P/FCF Ratio17.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)197.8
Revenue Forecast (FY)¥71.06B
ASKA Pharmaceutical Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the area...
How the Company Makes Money
ASKA Pharmaceutical Holdings Co., Ltd. primarily makes money through its consolidated pharmaceutical operations. The core revenue stream is sales of prescription pharmaceuticals marketed by its operating subsidiaries to medical institutions and ph...
ASKA Pharmaceutical Holdings Co., Ltd. Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
85
Very Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.43B | 71.13B | 64.14B | 62.84B | 60.46B | 56.61B |
| Gross Profit | 31.79B | 34.15B | 31.34B | 30.66B | 28.59B | 26.35B |
| EBITDA | 7.39B | 5.83B | 7.58B | 9.16B | 8.24B | 7.68B |
| Net Income | 5.07B | 5.42B | 5.10B | 7.54B | 4.24B | 4.29B |
Balance Sheet | ||||||
| Total Assets | 102.95B | 112.01B | 103.25B | 93.31B | 87.14B | 83.30B |
| Cash, Cash Equivalents and Short-Term Investments | 7.23B | 11.02B | 11.16B | 17.24B | 17.91B | 17.10B |
| Total Debt | 13.77B | 3.27B | 10.90B | 9.48B | 12.62B | 14.05B |
| Total Liabilities | 33.72B | 35.56B | 34.06B | 31.38B | 32.60B | 34.40B |
| Stockholders Equity | 65.44B | 69.99B | 65.31B | 61.93B | 54.53B | 48.89B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.75B | -475.00M | 166.00M | 2.89B | 2.26B |
| Operating Cash Flow | 0.00 | 6.30B | 2.48B | 1.49B | 3.35B | 2.84B |
| Investing Cash Flow | 0.00 | -5.75B | -6.12B | 1.71B | -1.13B | 6.74B |
| Financing Cash Flow | 0.00 | -818.00M | -2.96B | -3.94B | -1.82B | -3.00B |
ASKA Pharmaceutical Holdings Co., Ltd. Technical Analysis
Positive
2038.00
Price Trends
2641.75
Positive
2440.65
Positive
2315.45
Positive
Market Momentum
48.25
Positive
62.53
Neutral
75.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4886, the sentiment is Positive. The current price of 2038 is below the 20-day moving average (MA) of 2872.80, below the 50-day MA of 2641.75, and below the 200-day MA of 2315.45, indicating a bullish trend. The MACD of 48.25 indicates Positive momentum. The RSI at 62.53 is Neutral, neither overbought nor oversold. The STOCH value of 75.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4886.
ASKA Pharmaceutical Holdings Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥79.70B | 12.35 | ― | 2.52% | 10.90% | 6.20% | |
68 Neutral | ¥56.48B | 38.20 | 5.01% | 2.39% | 17.31% | -24.31% | |
66 Neutral | ¥120.46B | 19.64 | 4.81% | 2.34% | 11.21% | 39.02% | |
63 Neutral | ¥36.59B | 10.42 | ― | 2.75% | 3.94% | 40.63% | |
54 Neutral | ¥68.48B | 27.41 | ― | 3.36% | -2.94% | -62.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥147.14B | 52.56 | -2.58% | 4.16% | -18.25% | -84.71% |
* Healthcare Sector Average
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,830.00
572.34
25.35%
JP:4521
Kaken Pharmaceutical Co
4,080.00
490.61
13.67%
JP:4554
Fuji Pharma Co., Ltd.
2,193.00
928.62
73.44%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,495.00
598.67
20.67%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,294.00
-110.34
-7.86%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,214.00
254.44
26.52%
ASKA Pharmaceutical Holdings Co., Ltd. Corporate Events
ASKA Pharmaceutical Overhauls Board, Taps Industry Veteran for Governance Role
May 11, 2026
ASKA Pharmaceutical Holdings announced a slate of board and corporate officer changes set to take effect following its June 24, 2026 shareholders meeting, underscoring a governance reshuffle as the company navigates its next phase of growth. The c...
ASKA Pharmaceutical Delivers Record FY2025 Results on Overseas Expansion and Margin Gains
May 11, 2026
ASKA Pharmaceutical Holdings reported consolidated net sales of ¥71.1 billion for FY2025, a 10.9% year-on-year increase, driven by steady growth in its domestic business and contributions from overseas subsidiaries, leading to a record-high o...
ASKA Pharmaceutical Boosts Dividend as Profits Rise but Signals Margin Pressure Ahead
May 11, 2026
ASKA Pharmaceutical Holdings reported consolidated net sales of ¥71.1 billion for the fiscal year ended March 31, 2026, up 10.9% year-on-year, with operating profit rising 9.4% to ¥5.8 billion and profit attributable to owners of the par...
ASKA Pharmaceutical Lifts Dividend and Adopts Progressive Payout Policy
May 11, 2026
ASKA Pharmaceutical Holdings plans to raise its year-end dividend for the fiscal year ended March 31, 2026, to 33 yen per share, bringing the total annual dividend to 60 yen when combined with the 27 yen interim payout. This represents a 5 yen inc...
ASKA Pharmaceutical Board Rejects Activist Shareholder’s Director Proposal
May 11, 2026
ASKA Pharmaceutical Holdings has disclosed that it will oppose a shareholder proposal submitted by Nippon Active Value Fund PLC ahead of its June 24 annual general meeting, which calls for the appointment of two directors who are not audit and sup...
ASKA sets 2035 long-term vision and unveils 2028 medium-term growth plan
Mar 23, 2026
ASKA Pharmaceutical Holdings has unveiled a long-term management blueprint dubbed ASKA VISION 2035, setting a 10-year ambition to achieve sustainable growth while enhancing its contribution to society through purpose-driven business execution. The...
ASKA Pharma Launches Restricted Stock Plan for Employee Shareholders
Mar 2, 2026
ASKA Pharmaceutical Holdings has approved the introduction of a restricted stock incentive plan for members of its Employee Stock Ownership Association across the group, excluding corporate officers. The scheme will allow eligible employees to acq...
ASKA Pharmaceutical to Adopt Audit Committee Structure and Streamline Governance
Mar 2, 2026
ASKA Pharmaceutical Holdings will shift to a company structure with an audit committee, pending shareholder approval at its June 24, 2026 general meeting. The new framework will place a majority of outside directors on the audit committee to stren...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.